Phase 1 Prostate Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are generally well enough to carry out daily activities with little to no limitation (this is measured using a standard scale called ECOG, where a score of 0 or 1 is required)
• People who have been diagnosed with prostate cancer that has spread to other parts of the body, of a specific type (adenocarcinoma) that does not have small-cell or neuroendocrine features
• People who have previously been treated with a newer type of hormone therapy that targets the androgen receptor, such as abiraterone, enzalutamide, apalutamide, or darolutamide
• People who have previously been treated with a chemotherapy drug called a taxane, or who a doctor has determined are not suitable for taxane treatment, or who have chosen not to have taxane treatment
• People with a known BRCA1 or BRCA2 gene mutation who have previously been treated with a type of drug called a PARP inhibitor, or who a doctor has determined are not suitable for PARP inhibitor treatment (this applies where such treatment is approved and available)

Who may not be able to join:

• People who have received approved cancer treatment within the past 14 to 28 days before the trial starts (the exact timeframe depends on the specific drug used — confirm with trial site)
• People who have taken part in another clinical trial and received an experimental treatment within the past 28 days before the trial starts
• People who have previously been treated with a type of drug called an AR protein degrader
• People who have cancer that has spread to the brain or the lining around the brain or spinal cord that has not yet been treated

Important: Always verify eligibility with the trial site directly before applying.